Advertisement
Screener

Crinetics Pharmaceuticals, Inc. (CRNX) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

Crinetics Pharmaceuticals, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

Crinetics Pharmaceuticals, Inc. (CRNX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 2.06 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.

Financial Statements › Shareholders' Equity

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-08-03

  • Crinetics Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-06-30 was 255.90K shares, a 41.27% decline year-over-year.
  • Crinetics Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-03-31 was 1.81M shares, a 15.96% decline year-over-year.
  • Crinetics Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-12-31 was 160.43K shares, a 68.21% decline year-over-year.
  • Crinetics Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-09-30 was 292.98K shares, a 27.19% decline year-over-year.
  • Crinetics Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 3.04M shares, a 23.45% decline from fiscal 2024.
  • Crinetics Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 3.97M shares, a 17.74% decline from fiscal 2023.
  • Crinetics Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 4.82M shares, a 99.88% decline from fiscal 2022.
  • Crinetics Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2022 was 4.14B shares, a 43.27% increase from fiscal 2021.
Period endShare-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 monthShare-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 monthShare-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 monthShare-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month
2026-06-30255.90K shares
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03
2.06M shares
10-Q · filed 2026-08-03
2.22M shares
derived: sum of 3 quarters · filed 2026-08-03
2.52M shares
derived: sum of 4 quarters · filed 2026-08-03
2026-03-311.81M shares
10-Q · filed 2026-05-07
1.97M shares
derived: sum of 2 quarters · filed 2026-05-07
2.26M shares
derived: sum of 3 quarters · filed 2026-05-07
2.70M shares
derived: sum of 4 quarters · filed 2026-05-07
2025-12-31160.43K shares
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26
453.40K shares
derived: sum of 2 quarters · filed 2026-02-26
889.15K shares
derived: sum of 3 quarters · filed 2026-02-26
3.04M shares
10-K · filed 2026-02-26
2025-09-30292.98K shares
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06
728.73K shares
derived: sum of 2 quarters · filed 2025-11-06
2.88M shares
10-Q · filed 2025-11-06
3.38M shares
derived: sum of 4 quarters · filed 2025-11-06
2025-06-30435.75K shares
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07
2.58M shares
10-Q · filed 2025-08-07
3.09M shares
derived: sum of 3 quarters · filed 2025-08-07
3.49M shares
derived: sum of 4 quarters · filed 2025-08-07
2025-03-312.15M shares
10-Q · filed 2025-05-08
2.65M shares
derived: sum of 2 quarters · filed 2025-05-08
3.06M shares
derived: sum of 3 quarters · filed 2025-05-08
3.60M shares
derived: sum of 4 quarters · filed 2025-05-08
2024-12-31504.70K shares
derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27
907.10K shares
derived: sum of 2 quarters · filed 2025-02-27
1.45M shares
derived: sum of 3 quarters · filed 2025-02-27
3.97M shares
10-K · filed 2025-02-27
2024-09-30402.40K shares
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12
945.20K shares
derived: sum of 2 quarters · filed 2024-11-12
3.46M shares
10-Q · filed 2024-11-12
4.26M shares
derived: sum of 4 quarters · filed 2024-11-12
2024-06-30542.80K shares
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08
3.06M shares
10-Q · filed 2024-08-08
3.86M shares
derived: sum of 3 quarters · filed 2024-08-08
4.65M shares
derived: sum of 4 quarters · filed 2024-08-08
2024-03-312.52M shares
10-Q · filed 2024-05-09
3.32M shares
derived: sum of 2 quarters · filed 2024-05-09
4.11M shares
derived: sum of 3 quarters · filed 2024-05-09
5.17M shares
derived: sum of 4 quarters · filed 2024-05-09
2023-12-31796.70K shares
derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28
1.59M shares
derived: sum of 2 quarters · filed 2024-02-28
2.65M shares
derived: sum of 3 quarters · filed 2024-02-28
4.82M shares
10-K · filed 2024-02-28
2023-09-30795.31K shares
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07
1.86M shares
derived: sum of 2 quarters · filed 2023-11-07
4.03M shares
10-Q · filed 2023-11-07
4.14B shares
derived: sum of 4 quarters · filed 2023-11-07
2023-06-301.06M shares
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08
3.23M shares
10-Q · filed 2023-08-08
4.14B shares
derived: sum of 3 quarters · filed 2023-08-08
4.14B shares
derived: sum of 4 quarters · filed 2023-08-08
2023-03-312.17M shares
10-Q · filed 2023-05-09
4.14B shares
derived: sum of 2 quarters · filed 2023-05-09
4.14B shares
derived: sum of 3 quarters · filed 2023-05-09
4.14B shares
derived: sum of 4 quarters · filed 2023-05-09
2022-12-314.14B shares
derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28
4.14B shares
derived: sum of 2 quarters · filed 2023-02-28
4.14B shares
derived: sum of 3 quarters · filed 2023-02-28
4.14B shares
10-K · filed 2023-02-28
2022-09-30507.82K shares
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14
1.38M shares
derived: sum of 2 quarters · filed 2022-11-14
3.04M shares
10-Q · filed 2022-11-14
2.89B shares
derived: sum of 4 quarters · filed 2022-11-14
2022-06-30877.05K shares
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-12
2.53M shares
10-Q · filed 2022-08-12
2.89B shares
derived: sum of 3 quarters · filed 2022-08-12
2.89B shares
derived: sum of 4 quarters · filed 2022-08-12
2022-03-311.65M shares
10-Q · filed 2022-05-12
2.89B shares
derived: sum of 2 quarters · filed 2022-05-12
2.89B shares
derived: sum of 3 quarters · filed 2022-05-12
2.89B shares
derived: sum of 4 quarters · filed 2022-05-12
2021-12-312.89B shares
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30
2.89B shares
derived: sum of 2 quarters · filed 2022-03-30
2.89B shares
derived: sum of 3 quarters · filed 2022-03-30
2.89B shares
10-K · filed 2022-03-30
2021-09-30690.00 shares
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-05
986.00 shares
derived: sum of 2 quarters · filed 2021-11-05
2.59K shares
10-Q · filed 2021-11-05
1.61M shares
derived: sum of 4 quarters · filed 2021-11-05
2021-06-30296.00 shares
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10
1.90K shares
10-Q · filed 2021-08-10
1.61M shares
derived: sum of 3 quarters · filed 2021-08-10
1.61M shares
derived: sum of 4 quarters · filed 2021-08-10
2021-03-311.60K shares
10-Q · filed 2021-05-06
1.60M shares
derived: sum of 2 quarters · filed 2021-05-06
1.61M shares
derived: sum of 3 quarters · filed 2021-05-06
1.61M shares
derived: sum of 4 quarters · filed 2021-05-06
2020-12-311.60M shares
derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-30
1.60M shares
derived: sum of 2 quarters · filed 2021-03-30
1.60M shares
derived: sum of 3 quarters · filed 2021-03-30
1.60M shares
10-K · filed 2021-03-30
2020-09-30323.00 shares
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-06
538.00 shares
derived: sum of 2 quarters · filed 2020-11-06
1.34K shares
10-Q · filed 2020-11-06
48.54K shares
derived: sum of 4 quarters · filed 2020-11-06
2020-06-30215.00 shares
derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-07
1.02K shares
10-Q · filed 2020-08-07
48.22K shares
derived: sum of 3 quarters · filed 2020-08-07
128.07K shares
derived: sum of 4 quarters · filed 2020-08-07
2020-03-31804.00 shares
10-Q · filed 2020-05-08
48.00K shares
derived: sum of 2 quarters · filed 2020-05-08
127.85K shares
derived: sum of 3 quarters · filed 2020-05-08
300.13K shares
derived: sum of 4 quarters · filed 2020-05-08
2019-12-3147.20K shares
derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-09
127.05K shares
derived: sum of 2 quarters · filed 2020-03-09
299.32K shares
derived: sum of 3 quarters · filed 2020-03-09
900.17K shares
10-K · filed 2020-03-09
2019-09-3079.85K shares
derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12
252.13K shares
derived: sum of 2 quarters · filed 2019-11-12
852.98K shares
10-Q · filed 2019-11-12
903.42K shares
derived: sum of 4 quarters · filed 2019-11-12
2019-06-30172.28K shares
derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-13
773.13K shares
10-Q · filed 2019-08-13
823.58K shares
derived: sum of 3 quarters · filed 2019-08-13
909.36K shares
derived: sum of 4 quarters · filed 2019-08-13
2019-03-31600.85K shares
10-Q · filed 2019-05-13
651.30K shares
derived: sum of 2 quarters · filed 2019-05-13
737.09K shares
derived: sum of 3 quarters · filed 2019-05-13
2018-12-3150.45K shares
derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-13
136.24K shares
derived: sum of 2 quarters · filed 2019-03-13
2.00M shares
10-K · filed 2019-03-13
2018-09-3085.79K shares
derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-13
1.95M shares
10-Q · filed 2018-11-13
2018-06-301.87M shares
10-Q · filed 2018-08-30